Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.15 USD

76.15
421,444

+0.21 (0.28%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons Why You Should Retain ResMed (RMD) Stock For Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA), backed by continued partnership growth and a strong focus on strategic execution.

Masimo (MASI) PVi Achieves Acceptable Fluid Response in Study

by Zacks Equity Research

Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.

Charles River's (CRL) New Cloud Platform Offers Real-Time Data

by Zacks Equity Research

Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.

Illumina (ILMN) Unveils Complete Long Reads Technology

by Zacks Equity Research

Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.

Syneos Health's (SYNH) Product Launch Aids, FX Woe Hurts

by Zacks Equity Research

Syneos Health (SYNH) remains confident about the long-term strength of its business, given its robust backlog and unique market position.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by strength in its Drug Development business.

Henry Schein (HSIC) Aids Growth of Ambulatory Surgery Centers

by Zacks Equity Research

Henry Schein (HSIC) joined ASCA as part of its commitment to augment the value of ambulatory surgery centers.

Henry Schein (HSIC) International Growth Solid, Dental Rebounds

by Zacks Equity Research

Henry Schein's (HSIC) distribution business boasts a wide global footprint with 61 distribution centers.

Charles River (CRL) Advances CDMO Portfolio With Latest Offer

by Zacks Equity Research

Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.

Abbott (ABT) to Pair CGM Sensors & AID System on FDA Clearance

by Zacks Equity Research

Abbott Laboratories (ABT) receives FDA clearance for the integration of its iCGM system sensors with automated insulin delivery (AID) systems.

Charles River (CRL) Hurt by NHP Shipment Issue, FX Woes

by Zacks Equity Research

The investigation related to the current NHP supply situation is likely to result in study delays in Charles River's (CRL) Safety Assessment business.

Thermo Fisher (TMO) Introduces iCAP RQplus ICP-MS Analyzer

by Zacks Equity Research

Thermo Fisher's (TMO) new analyzer streamlines everyday analyses in environmental, food, pharmaceutical and industrial testing laboratories.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS), backed by the announcement of entering into a colossal $10.6-billion acquisition agreement to purchase Oak Street Health.

QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

by Zacks Equity Research

QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.

Here is Why Growth Investors Should Buy Haemonetics (HAE) Now

by Zacks Equity Research

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO), owing to robust demand in Life Science and Clinical Diagnostics arms.

Thermo Fisher (TMO) Unveils New Line of Low-Flow HPLC Columns

by Zacks Equity Research

Thermo Fisher's (TMO) newest addition of a new line of low-flow HPLC columns that improve separation performance and stability of biologically complex samples.

Smith & Nephew (SNN) Simplifies ACL Surgery With New Offers

by Zacks Equity Research

Smith & Nephew (SNN) introduces QUADTRAC System and broadens ULTRABUTTON Adjustable Fixation Devices portfolio for ACL reconstruction.

Bio-Rad (BIO) Global Expansion Strong, FX Woe Dents Growth

by Zacks Equity Research

Bio-Rad (BIO) experiences double-digit currency-neutral core revenue growth in the Americas and Asia in Q4.

Abbott (ABT) Gets FDA Nod for Alinity I Laboratory Test

by Zacks Equity Research

Abbott's (ABT) Alinity i TBI lab test provides a new reliable result in 18 minutes to support clinicians in quickly assessing concussion and triaging patients.

LabCorp (LH) Focuses on High-Growth Areas Amid Currency Woe

by Zacks Equity Research

In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, autoimmune and liver disease as well as cell and gene therapy.

Orthofix (OFIX) Progresses With Limb-Lengthening Device

by Zacks Equity Research

Orthofix's (OFIX) Fitbone TAA intramedullary limb-lengthening system is implanted through a minimally invasive procedure.

Abbott (ABT) Reveals Favorable Data on Tricuspid Regurgitation

by Zacks Equity Research

Abbott Laboratories (ABT) demonstrates the superiority of the TriClip device in treating patients with severe, symptomatic tricuspid regurgitation.

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.